
New Weight Loss & Heart Drug Shows Significant Benefits in Major Trial of Obese Patients
Tirzepatide improved heart and kidney outcomes in patients with obesity, HFpEF, and CKD, showing a 38% reduction in cardiovascular death or worsening heart failure and consistent benefits across patient subgroups. The drug enhances outcomes in a high-risk …